Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Intervacc AB logo — A new generation of vaccines based on fusions of recombinant...

Intervacc AB

A new generation of vaccines based on fusions of recombinant proteins

Founded 2001 Sweden Sweden 13 employees Grant Total: $30.00M Biotechnology, Health Care +1

General Information

Company Name Intervacc AB
Founded Year 2001
Location Sweden Sweden +1
Employees 13
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Grant
Social

Get notified when Intervacc AB moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Intervacc AB

Intervacc AB is a biotechnology company based in Sweden that focuses on developing a new generation of vaccines within animal health. The company's slogan, "A new generation of vaccines based on fusions of recombinant proteins," captures its innovative approach to vaccine development. Since its founding in 2001, Intervacc AB has been at the forefront of creating vaccines based on recombinant proteins to address the growing demand for effective and safe vaccines in animal healthcare. The company's commitment to leveraging recombinant proteins in vaccine development aligns with the increasing emphasis on safety and efficacy in the healthcare industry. This approach positions Intervacc AB at the intersection of biotechnology, health care, and pharmaceutical industries, indicating the potential for significant impact and growth. Recently, Intervacc AB received a grant investment from Vinnova on 17 August 2023, underscoring the confidence of investors in the company's innovative vaccine technologies. This investment not only provides financial support but also signifies external validation of the company's potential to make a meaningful contribution to animal health care. Overall, Intervacc AB's focus on developing vaccines based on recombinant proteins, coupled with its recent grant investment, positions the company as an exciting player in the biotechnology and animal health sectors. With a strong emphasis on safety and effectiveness, Intervacc AB is poised to make a significant impact on animal health and the broader pharmaceutical industry.

Taxonomy: veterinary, vaccines, animal health, biotech, recombinant vaccines, microbiology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
17 Aug 2023
Venture Round •••••• 1
Investor
20 Dec 2010

Intervacc AB Alternatives & Competitors

Intervacc AB vs
MEVAC for Vaccines
MEVAC for Vaccines Egypt

Science , Innovation , Quality

298 employees
Health Care
Intervacc AB vs
Tréidlia Biovet
Tréidlia Biovet Australia

Designing Specialised Biotechnological Solutions for Animal Health

54 employees
Biotechnology, Pharmaceutical
Intervacc AB vs
Hester & Co
Hester & Co

Crafting innovations in poultry and large animal health, enhancing wellness with vaccines, feed supp...

Grant
2-10 employees
Agriculture, Biotechnology

FAQ About Intervacc AB

A new generation of vaccines based on fusions of recombinant proteins
Intervacc AB was founded in 2001.
Intervacc AB is headquartered in Sweden.
Intervacc AB operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Intervacc AB has approximately 13 employees.
Intervacc AB has completed 2 funding rounds, raising a total of $30.00M. The latest funding stage is Grant.
Top alternatives and competitors to Intervacc AB include MEVAC for Vaccines , Tréidlia Biovet, Hester & Co, Mazen Animal Health - Oral Vaccines, Edge Animal Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Intervacc AB and MEVAC for Vaccines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Intervacc AB and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy